

RECEIVED  
CENTRAL FAX CENTER

DEC 02 2004

## FACSIMILE COVER SHEET

NORRIS MCLAUGHLIN &amp; MARCUS, P.A.

875 Third Avenue

18<sup>th</sup> Floor

New York, NY 10022

Tel.: (212) 808-0700

Fax.: (212) 808-0844

**Date:** December 2, 2004**To:** MAIL STOP AMENDMENT  
Examiner Michael T. Brannock  
US Patent and Trademark Office  
Fax: 703-872-9306**Subject:** USSN: 09/582,719  
Our Ref.: 101195-2**From:** Paul S. Lim**Comments:** Filing of: response to Office Action dated June 2, 2004, including Amendment under 37 CFR 1.111 (14 pgs.); and Petition for Three Months Extension of Time (2 pgs.)

If you have any questions or need further information, please contact us.

You should receive 17 pages including this cover sheet.

The information contained in this facsimile message is intended only for the personal and confidential use of the recipient(s) named above. This message may be an attorney-client communication and as such is privileged and confidential. If the reader of this message is not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby notified that you have received this document in error and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you have received this communication in error, please notify us immediately at the number above and discard the original message.

Application No. 09/582,719  
Amendment Dated December 2, 2004  
Reply to Office Action of June 2, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

SERIAL NO. : 09/582,719  
APPLICANT : Hoehe et al  
FILED : August 22, 2000  
EXAMINER : Michael T. Brannock  
ART UNIT : 1646  
FOR : NOVEL SEQUENCE VARIANTS OF THE HUMAN BETA  
2-ADRENERGIC GENE

RECEIVED  
CENTRAL FAX CENTER  
DEC 02 2004

December 2, 2004

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

AMENDMENT UNDER 37 CFR § 1.111

SIR:

In response to the Office Action dated June 2, 2004, please amend the above-identified application as follows:

**Amendments to the Specification** being on page 2 of this paper

**Amendments to the Claims** are reflected in the listing of claims which begins on page 3 of this paper.

**Remarks/Arguments** begin on page 11 of this paper